Q-omics provides the consensus-scored MIR1256 profile across patient tissues and cancer cell-line models. MIR1256 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR1256 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, MIR1256 RNA expression shows 7,828 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, HNSC, and GBM as cancer lineages where MIR1256 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1256 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1256 survival associations across molecular data types. MIR1256 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1256 RNA expression–survival associations across cancer types. High MIR1256 expression shows unfavorable associations in THCA, KIRP, PAAD, LIHC and THYM, but favorable associations in ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR1256 RNA expression.
This table summarizes MIR1256 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1256. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1256 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher MIR1256 RNA expression in tumor versus normal tissue (log2 FC = +0.084, t-test p = .014).
This table shows molecular features associated with MIR1256 in patient tissues and cancer cell lines. In patient samples, MIR1256 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
